Recto-vaginal Fistula Treatment Market (Type: High Recto-vaginal Fistula, Low Recto-vaginal Fistula, and Midzone Fistula; End-user; Indication and Treatment) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Recto-vaginal Fistula Treatment market was valued at USD 950.2 million in 2022 and it is expected to hit around USD 2.8 billion by 2030 with a CAGR of 6.7% during the forecast period 2022 to 2030.

Recto-vaginal Fistula Treatment Market: Overview

• Recto-vaginal fistula is an abnormal connection between lower portions of large intestine-rectum-vagina. Causes of rectovaginal fistula include Crohn's disease, cancer or radiation treatment in pelvic area, surgery involving vagina, perineum, rectum or anus, and injuries during childbirth.
• Fistula connects to surfaces or lumens. It begins on the offending side and makes its way to an adjacent lumen or surface. It follows the easiest and shortest path to the adjacent organ. Recto-vaginal fistula starts from the rectum and extends to the vagina. It is not a healthy situation or physiological status. There is usually an underlying pathology, injury, or surgical event. Characteristics of rectovaginal fistula (RVF), such as site, size, length, activity, and symptoms, vary depending on the cause of the fistula, patient factors, and the treatment received. It is a potentially challenging surgical condition for both the patient and the healthcare team. The underlying etiology determines the method of assessment, management, and prognosis.
• The frequency of recto-vaginal fistula varies according to the cause. These are typically classified by etiology, location, and size, which affect the treatment and prognosis. Recto-vaginal fistulas are divided into two groups by location:
• Low RVFs are located in the lower third of the rectum and the lower half of the vagina. These are closest to the anus and are repaired with a perineal surgical approach.
• High RVFs are located between the middle third of the rectum and the posterior vaginal fornix. These require a transabdominal surgical repair approach.
• Most RVFs are less than 2 cm in diameter and are stratified by size:
• Small: Less than 0.5 cm in diameter
• Medium-sized: 0.5 to 2.5 cm in diameter
• Large RVFs: Exceed 2.5 cm in diameter

Report Scope of the Recto-vaginal Fistula Treatment Market

Recto-vaginal Fistula Treatment Market: Drivers

• Rise in prevalence of Crohn’s disease leading to the occurrence of recto-vaginal fistula drives the global recto-vaginal fistula treatment market. Crohn's disease can be defined as an inflammatory bowel disease, wherein there is an inflammation of the digestive tract lining. Large number of women suffering from Crohn’s disease never develop recto-vaginal fistula. However, Crohn’s disease increases the risk of this condition. Hence, prevalence of recto-vaginal fistula is projected to rise during the forecast period owing to increase in incidence of Crohn’s disease.
• Delivery-related injuries is the most common factor causing recto-vaginal fistulas. This includes perineum tear that extends to the bowel or an episiotomy infection, which is a surgical incision conducted to enlarge the perineum during the course of vaginal delivery. These could occur post a long, difficult, or otherwise obstructed labor. These kinds of fistula could also comprise injury to anal sphincter, the muscle rings at the end of the rectum that aid a person to hold. Hence, the incidence rate of recto-vaginal fistula is likely to increase due to rise in the rate of childbirth injuries during the forecast period.
• Presence of cancerous tumor in regions, such as uterus, rectum, vagina, anal canal or cervix, can lead to development of recto-vaginal fistula. Moreover, radiation therapy undertaken to treat cancer in these body parts increases the risk of development of recto-vaginal fistulas. Past surgery in lower pelvic region, such as hysterectomy, could also result in development of recto-vaginal fistula. Therefore, rise in prevalence of pelvic cancer and surgery in lower pelvic region are projected to drive the global recto-vaginal fistula market.

Market Segmentation: Recto-vaginal Fistula Treatment Market

• In terms of type, the global recto-vaginal fistula treatment market has been classified into high rectovaginal fistula, low rectovaginal fistula, and midzone fistula
• Based on end-user, the global Rectovaginal fistula treatment market has been categorized into hospitals, ambulatory surgical centers, and others
• In terms of treatment, the global recto-vaginal fistula treatment market has been bifurcated into medication and surgery
• Based on indication, the global recto-vaginal fistula treatment market has been divided into Crohn's disease, delivery-related injuries, cancerous tumor treatment, and others
• Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The Recto-vaginal fistula treatment market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2030, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2030 along with market size estimations.

Home Remedies and Telehealth Ensure Revenue Growth Post COVID-19 Pandemic

Stakeholders in the recto-vaginal fistula treatment market are adopting contingency planning to prevent disruption across patient demands, supply of materials, and availability of diagnostic services. Since elective procedures have been postponed indefinitely due to the ongoing coronavirus pandemic, medical practitioners are increasing awareness about different tests for identifying fistulas, medications, and lifestyle or home remedies to reduce burden on healthcare facilities. As such, telehealth and mobile apps are anticipated to register high growth post the pandemic. Healthcare stakeholders are striking a balanced relationship with suppliers and ecosystem partners to improve medical outcomes. They are increasing the availability of life-altering therapeutics.

Healthcare Stakeholders Invest in R&D to Increase Treatment Options

Recto-vaginal fistula can be described as abnormal epithelial line connected between the rectum and vagina. Fistulas can be the outcome of acquired etiologies or congenital malformations. Recto-vaginal fistulas can also be caused due to childbirth. Obstetric injury with a fourth or a third degree perineal tear or prolonged labor with necrosis of the part or episiotomy could result in recto-vaginal fistula. Infection, breakdown of the repair, or improper repair can lead to the development of fistula. Infections caused within the recto-vaginal septum can lead to the condition. Bartholin gland infections and crypto-glandular ano-rectal abscess drains cause low recto-vaginal fistula. This explains why the recto-vaginal fistula treatment market is positioned for healthy growth during the forecast period.

Hysterectomy is performed as a result of infection caused due to fistula. Lymph granuloma venereum and tuberculosis can result in recto-vaginal fistula. Primary classification of the condition is carried out with the help of etiology, size, and location. It categorizes the criteria for recto-vaginal fistulas as complex or simple. Classification of fistula is performed to plan proper treatment and appropriate therapy. Fistulas greater than 2.5 cm in diameter are termed as large and those less than 2.5 cm are considered small. Hence, healthcare practitioners in the recto-vaginal fistula treatment market are increasing R&D to boost availability of therapeutics.

Robust Healthcare Infrastructure in North America Helps Increase Patient Outcomes

North America is anticipated to dominate the global recto-vaginal fistula treatment market from 2021 to 2030. This can be attributed to favorable regulatory environment, rise in focus and interest in recto-vaginal fistula research & development (R&D), and government funding for life sciences research. Additionally, well-established and high quality infrastructure are driving the North America recto-vaginal fistula treatment market. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to rise in R&D activities, increase in government initiatives for improving healthcare, and surge in focus of key players on building or strengthening presence in the region.

Governments of developing countries are making significant investments to modernize healthcare infrastructure in their respective countries, which is likely to increase access to healthcare. This is projected to fuel the demand for recto-vaginal fistula treatment.

Regional Overview: Recto-vaginal Fistula Treatment Market

• In terms of region, the global recto-vaginal fistula treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
• The recto-vaginal fistula treatment market in North America was valued at US$ 149.7 Mn in 2020 and is projected to reach US$ 425.8 Mn by 2030, expanding at a CAGR of 7.2% from 2021 to 2030
• Growth of the market in the region can be attributed to favorable regulatory environment, rise in focus and interest in recto-vaginal fistula research & development, and government funding for life sciences research. Additionally, well-established and high quality infrastructure drives the market in North America.

Some of the prominent players in the Recto-vaginal Fistula Treatment Market include:

• Pfizer, Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson Services, Inc.
• W. L. Gore & Associates, Inc.
• Mount Sinai Hospital
• Tubingen University Hospital
• St. Mark's Hospital
• Apollo Hospitals Enterprise Ltd.
• Other prominent players

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Recto-vaginal Fistula Treatment market

• By Type
• High Recto-vaginal Fistula
• Low Recto-vaginal Fistula
• Midzone Fistula
• By End-user
• Hospitals
• Ambulatory Surgical Centers
• Others
• By Indication
• Crohn's Disease
• Delivery-related Injuries
• Cancerous Tumor Treatment
• Others
• By Treatment
• Medication
• Antibiotics
• Biologics Therapy
• Surgery
• Sphincteroplasty Procedure
• Endorectal Advancement Flap Procedure
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Recto-vaginal Fistula Treatment industry analysis from 2022 to 2030 to identify the prevailing Recto-vaginal Fistula Treatment industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Recto-vaginal Fistula Treatment industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Recto-vaginal Fistula Treatment industry trends, key players, market segments, application areas, and market growth strategies.